Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl).
about
Role of Myeloperoxidase in Patients with Chronic Kidney DiseaseSite-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional.Thiocyanate supplementation decreases atherosclerotic plaque in mice expressing human myeloperoxidase.Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney Disease Patients Receiving Kidney Transplants.Tripping up Trp: Modification of protein tryptophan residues by reactive oxygen species, modes of detection, and biological consequencesWhy targeting HDL should work as a therapeutic tool, but has not.The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes.Cholesterol Efflux Capacity of Apolipoprotein A-I Varies with the Extent of Differentiation and Foam Cell Formation of THP-1 Cells.Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasmaAn abundant dysfunctional apolipoprotein A1 in human atheroma.ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease.Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit.Mitochondria-targeted spin traps: synthesis, superoxide spin trapping, and mitochondrial uptake.Elaidic acid (EA) generates dysfunctional high-density lipoproteins and consumption of EA exacerbates hyperlipidemia and fatty liver change in zebrafish.Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products.Multifunctional regulation of angiogenesis by high-density lipoproteins.Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease.
P2860
Q26748996-F9608016-930A-4C89-A968-D61E6301B856Q33675617-42473133-9F4D-4B05-A4C2-40B487985B2DQ35702958-5F0C32A0-BEED-4ADF-A294-40E40FEB2005Q36327959-58BA04E9-A6D2-43FD-B98A-8FAB065293A4Q36386406-0E28B9A3-3D8D-49BD-9DC6-FC13466652F2Q37170464-2B03E795-9663-431F-8AF4-9E06911E9FCAQ37211868-D5CAF464-1F9E-4A85-9A47-71F37557110AQ37430678-4C179FD0-4211-4EC1-9DBA-F65562C1F63EQ37441776-1C8C2C47-A824-4A1D-8C8B-B7E701D17525Q37581580-7BD6D9F2-3900-4112-BF95-66064E0903B6Q38835289-A5272DE0-A0D8-48B9-AFED-9D048DBF84CCQ41115717-7510A092-B432-47A1-ADFF-A1503F4799D8Q42232183-5558F398-5CF1-45E8-BC52-95BCF0B1E365Q46889706-1B4FCDF4-09A1-4D26-A4B3-0A6064B0F6B0Q49346082-4AF4B48B-3620-41A6-B777-44549B2D3F06Q54402657-E2D571D8-0BB4-4338-80A8-70F5F45BC6AFQ55347767-9F45090B-CA0A-442A-8A6B-C972FFF8BFF9
P2860
Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Myeloperoxidase-derived oxidan ...... with hypochlorous acid (HOCl).
@en
Myeloperoxidase-derived oxidan ...... arison of hypothiocyanous acid
@nl
type
label
Myeloperoxidase-derived oxidan ...... with hypochlorous acid (HOCl).
@en
Myeloperoxidase-derived oxidan ...... arison of hypothiocyanous acid
@nl
prefLabel
Myeloperoxidase-derived oxidan ...... with hypochlorous acid (HOCl).
@en
Myeloperoxidase-derived oxidan ...... arison of hypothiocyanous acid
@nl
P2093
P2860
P50
P356
P1433
P1476
Myeloperoxidase-derived oxidan ...... with hypochlorous acid (HOCl).
@en
P2093
David I Pattison
Katrina A Hadfield
Kerry-Anne Rye
P2860
P304
P356
10.1042/BJ20121210
P407
P577
2013-01-01T00:00:00Z